仅对制药厂、医药研发公司、医药研究所、医院提供信息服务,不对个人提供信息服务!

类别

搜索

地點

訂閱此搜索

5.33 Euro €

药品编号 13706664 持证商 URSAPHARM Arzneimittel GmbH 包装规格 15 ml 产品名 Pollicrom 20mg/ml 剂型 Nasenspray Monopräparat ja 活性物质 Cromoglicinsäure, Dinatriumsalz 需要医生开处方 nein Apothekenpflichtig ja 信息来源:https://www.besamex.de/product/pollicrom-20-mg-ml-nasenspray-loesung.645913.html

· 十一月 20, 2018
9.90 Euro €

药品编号 13748591 持证商 URSAPHARM Arzneimittel GmbH 包装规格 10 ml 产品名 Pollival 0,5mg/ml 剂型 Augentropfen Monopräparat ja 活性物质 Azelastin hydrochlorid 需要医生开处方 nein Apothekenpflichtig ja 信息来源:https://www.besamex.de/product/pollival-0-5-mg-ml-augentropfen-loesung.645941.html

· 十一月 20, 2018
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:55MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:45MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:35MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 212038Company: PURDUE PHARMA LPTreatment for: Attention-Deficit / Hyperactivity DisorderDate of Approval:02/27/2019DrugName:ADHANSIA XRActive Ingredients:METHYLPHENIDATE HYDROCHLORIDEStrength:25MGDosage Form:CAPSULE, EXTENDED RELEASEDosage Route:ORALTE Code...

· 五月 11, 2020
了解卖家

Biologic License Application (BLA): 761106Company: GENENTECH INCTreatment for: Breast CancerDate of Approval:02/28/2019DrugName:HERCEPTIN HYLECTAActive Ingredients:TRASTUZUMAB; HYALURONIDASE-OYSKStrength:600MG;10000UNITSDosage Form:INJECTABLEDosage Route:SUBCUTANEOUSTE Code:NoneRLD:NoRS:No...

· 五月 11, 2020
了解卖家

New Drug Application (NDA): 208711Company: NOVARTISTreatment for: FascioliasisDate of Approval:02/13/2019DrugName:EGATENActive Ingredients:TRICLABENDAZOLEStrength:250MGDosage Form:TABLETDosage Route:ORALTE Code:NoneRLD:YesRS:YesNDC:0078-0937-91Approval Letter(s) (PDF)Printed Labe...

· 五月 11, 2020
了解卖家

Biologic License Application (BLA): 761112Company: ABLYNX NVTreatment for: Acquired Thrombotic Thrombocytopenic PurpuraDate of Approval:02/06/2019DrugName:CABLIVIActive Ingredients:CAPLACIZUMAB-YHDPStrength:11MG/VIALDosage Form:INJECTABLEDosage Route:INJECTIONTE Code:NoneRLD:NoRS:NoNDC:584...

· 五月 8, 2020
了解卖家

Biologic License Application (BLA): 761085Company: EVOLUS INCTreatment for: Glabellar LinesDate of Approval:02/01/2019DrugName:JEUVEAUActive Ingredients:PRABOTULINUMTOXINA-XVFSStrength:100 UNITSDosage Form:INJECTABLEDosage Route:INJECTIONTE Code:NoneRLD:NoRS:NoNDC:72301-595-10Start Marketi...

· 五月 8, 2020
了解卖家

New Drug Application (NDA): 210942Company: AVION PHARMSTreatment for: GoutDate of Approval:01/30/2019DrugName:GLOPERBAActive Ingredients:COLCHICINEStrength:0.6MG/5MLDosage Form:SOLUTIONDosage Route:ORALTE Code:NoneRLD:YesRS:YesNDC:72690-010-05Start Marketing Date: 08-01-2019 List...

· 五月 8, 2020
了解卖家

New Drug Application (ANDA): 208891Company: MYLANTreatment for: Asthma, Chronic Obstructive Pulmonary DiseaseDate of Approval:01/30/2019DrugName:WIXELA INHUBActive Ingredients:FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEStrength:0.5MG/INH;EQ 0.05MG BASE/INHDosage Form:POWDERDosage Rou...

· 五月 8, 2020
Top